Ryan H. Flax
67 IP cases indexed. Covers patent matters.
Cases Presided Over
67 cases indexed | Page 1 of 3
Anker Innovations Ltd. v.Powermat Technologies Ltd.
Anker Innovations and Powermat Technologies settled their wireless‑charging patent dispute in IPR2024‑00995. The Board terminated the proceeding and ordered the settlement agreement to be kept confidential.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB held that all 20 claims of Exact Sciences' 11,634,781 patent are obvious over prior art, rendering them unpatentable. Geneoscopy successfully proved the combination of existing fecal screening methods made the claims non‑inventive.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their IPR dispute over U.S. Patent 7,776,120, leading the PTAB to terminate the proceeding before any merits were decided.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
The PTAB denied NeoGenomics’s petition to institute an IPR against Natera’s 11,530,454 patent covering liquid‑biopsy methods. The Board found the prior art had already been considered and no material error existed. No trial will be held.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB found all 20 claims of the '11634781 patent unpatentable as obvious under 35 U.S.C. § 103. The Board concluded that combining prior art references, specifically Lenhard, Vilkin, and Itzkowitz, taught or suggested every element of independent claim 1 with a reasonable expectation of success. This decision rejects the Patent Owner's arguments regarding lack of motivation to combine the cited art.
Anker Innovations Limited v.Powermat Technologies Ltd.
The PTAB issued a Final Written Decision finding that claims 1–7 and 9–14 were unpatentable over prior art references. The petitioner successfully demonstrated obviousness under 35 U.S.C. § 103, particularly regarding the combination of Onishi and Flowerdew for independent claim 1.
Geneoscopy, Inc. v.Exact Sciences Corporation
The PTAB issued a Final Written Decision finding all challenged claims unpatentable under 35 U.S.C. § 103. The Petitioner successfully argued that the claimed colorectal cancer screening method was obvious when combining various prior art references, including Lenhard, Vilkin, Itzkowitz, and Kanaoka.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
The PTAB instituted the IPR after finding a reasonable likelihood of success that the challenged claims are unpatentable based on obviousness (35 U.S.C. § 103). The Board analyzed key claim terms, preliminarily construing 'validated' as a negative test result rather than release into commerce.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully initiated an IPR against Institute for Environmental Health, Inc.'s microbial testing patent (8822143). The Board adopted a narrow definition of 'validated' as merely determining a sample tests negative using the detection assay.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully petitioned to institute IPR against the '771 patent, establishing a reasonable likelihood of success over at least one claim. The Board adopted Petitioner's definition for 'validation,' clarifying that it merely requires a sample test negative, rejecting the Patent Owner's broader interpretation regarding commercial release.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories successfully secured institution status for an IPR against Eye Therapies, LLC regarding ophthalmic formulations. The Board found a reasonable likelihood of prevailing on obviousness (35 U.S.C. § 103) based on the combination of prior art references.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
The PTAB instituted the IPR petition challenging key claims of a patent related to vasoconstriction agents for eye redness. The Board found that Petitioner demonstrated a reasonable likelihood of prevailing, despite arguments from the Patent Owner regarding prior art limitations and adverse events.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson Technology Limited successfully established a reasonable likelihood of prevailing in its IPR against Omachron Intellectual Property regarding vacuum cleaner technology. The Board found that combinations of prior art references rendered multiple claims obvious or anticipated.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson Technology Limited successfully petitioned to challenge Omachron Intellectual Property Inc.'s patent claims in a PTAB IPR proceeding, leading the Board to institute the trial on all 28 claims. The institution decision hinged on sufficient evidence of obviousness over prior art references Peter and Neroni.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson successfully petitioned the PTAB to institute IPR proceedings against a patent covering cleaning apparatuses. The Board found reasonable likelihood of prevailing on grounds of anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103).
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
The PTAB denied Dyson's IPR challenge against Omachron's vacuum cleaner patent (10,568,477). The Board found that the Petitioner failed to demonstrate a reasonable likelihood of success, rejecting arguments based on prior art references like Brown and Dimbylow.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully challenged claims 1-30 of the '486 patent in a PTAB Institution Decision, establishing a reasonable likelihood that the methods for pathogen detection are unpatentable. The petitioner relied on prior art references including Rayman and Nagar to demonstrate anticipation and obviousness across multiple grounds.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.
Arthrex, Inc. et al. v.Medshape, Inc.
The PTAB denied Arthrex's IPR petition against Medshape's patent (7985222), citing the complex and overlapping nature of co-pending district court litigation.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Green Revolution Cooling, Inc. v.Midas Green Technologies, LLC
Green Revolution Cooling, Inc. successfully secured institution at the PTAB against Midas Green Technologies, LLC regarding claims covering appliance immersion cooling systems. The Board found that the petitioner met the burden of proof for obviousness under 35 U.S.C. § 103 based on prior art references Best-2008 and Osada.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned to institute IPR against Merus N.V.'s patent (11926859) covering heterodimeric antibodies. The Board found reasonable likelihood of unpatentability based on written description and obviousness grounds.
Cimbra SRL et al. v.3U Vision SRL
Cimbra SRL challenged 3U Vision's optical sorting patent (11666947) on grounds of obviousness and indefiniteness, specifically over the prior art reference ElMasry. The PTAB preliminarily agreed that it is more likely than not that at least one claim would be unpatentable, instituting the proceeding for trial phase.
GD Energy Products, LLC v.Kerr Machine Company
GD Energy Products successfully petitioned the PTAB to institute an IPR against Kerr Machine Company's pump patent, alleging obviousness under 35 U.S.C. § 103. The Board found it more likely than not that at least one claim would be unpatentable over various prior art references related to fluid end assemblies.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.